20/20 Biolabs Inc. (AIDX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 10 | 11 | 1 | 2 | 2 | 2 | 3 |
| Operating profit | $m | -3 | -4 | ||||||
| Net profit | $m | -2 | 2 | 2 | -6 | -6 | -4 | -6 | -3 |
| EPS reported | $ | -0.60 | -0.76 | ||||||
| Operating cashflow per share | $ | -306.8 | -0.26 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -306.8 | -0.26 | ||||||
| Free cash flow | $m | -1,920 | -3 | ||||||
| Net debt | $m | 258 | -5 | ||||||
| Book value equity | $m | -19 | - | ||||||
| Book value per share | $ | -3.07 | 0.29 | ||||||
| Number of shares | m | 6.26 | 10.79 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.01 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -7.76 | 2.02 | ||||||
| P/S LTM | x | 72.96 | 73.14 | ||||||
| P/FCF LTM | x | -0.08 | -53.55 | ||||||
| EV/EBITDA LTM | x | -116.21 | -84.91 | ||||||
| EV/Sales LTM | x | 199.14 | 1.60 | ||||||
| Earnings Yield LTM | % | -2.51% | -91.10% | ||||||
| FCF Yield | % | -1286.50% | -1.87% | ||||||
| Quality | |||||||||
| ROE | % | +19447.70% | -387.27% | ||||||
| ROIC | % | -1.87% | -1.17% | ||||||
| Operating margin | % | -1.63% | -2.16% | ||||||
| Gross margin | % | +29.56% | +31.52% | ||||||
| FCF/Sales | % | -93867.73% | -136.57% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +16.71% | +16.43% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.50 | -4.87 | ||||||
| Net Debt/EBITDA | x | -73.63 | 0.83 | ||||||
| EBIT/Net interest | x | -21.32 | -6.34 | ||||||
| Net debt/market cap | % | +1.18% | +7.90% | ||||||
| Net debt/Equity | x | -13.42 | - | ||||||
| Gross debt/equity | x | -66.79 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free